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Abstract
Aberrantly high expression of EVI1 in acute myeloid leukaemia (AML) is associated with poor prognosis. For targeted treat-
ment of EVI1 overexpressing AML a more detailed understanding of aspects of spatiotemporal interaction dynamics of the 
EVI1 protein is important. EVI1 overexpressing SB1690CB AML cells were used for quantification and protein interaction 
studies of EVI1 and ΔEVI1. Cells were cell cycle-synchronised by mimosine and nocodazole treatment and expression of 
EVI1 and related proteins assessed by western blot, immunoprecipitation and immunofluorescence. EVI1 protein levels 
oscillate through the cell cycle, and EVI1 is degraded partly by the proteasome complex. Both EVI1 and ΔEVI1 interact 
with the co-repressor CtBP1 but dissociate from CtBP1 complexes during mitosis. Furthermore, a large fraction of EVI1, but 
not ΔEVI1 or CtBP1, resides in the nuclear matrix. In conclusion, EVI1- protein levels and EVI1-CtBP1 interaction dynam-
ics vary though the cell cycle and differ between EVI1 and ΔEVI1. These data ad to the functional characterisation of the 
EVI1 protein in AML and will be important for the development of targeted therapeutic approaches for EVI1-driven AML.
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Introduction
Aberrantly high expression of EVI1 in acute myeloid leu-
kaemia (AML) is commonly caused by chromosomal aber-
rations involving the MECOM (MDS-EVI1 complex) locus 
at 3q26 and associated with poor outcome [1, 2]. In AML, 
the overexpressed 1051 amino acid (aa) EVI1 protein can be 
co-expressed with the shorter ΔEVI1 isoform, which lacks 
a 324 aa sequence region (aa190-514), including the 6th 
and 7th zinc finger of the N-terminal zinc finger domain 
(Fig. 1a). The MDS-EVI1 isoform is usually not expressed 
at elevated levels [2]. DNA binding sites of the ΔEVI1 iso-
form largely overlap with those of EVI1, but it lacks in vivo 
transforming ability characteristic for EVI1 [3, 4]. While 
the reliance of EVI1 on interaction with other transcription-
ally active proteins, e.g. CtBP1 [5], has been recognised and 
provides potential angles for therapeutic approaches, spati-
otemporal dynamics of the EVI1 protein isoforms in AML 
are incompletely understood, but would be important for 
the development of EVI1-targeted therapeutic approaches. 
Here, we report on data that uncover cell cycle and isoform 
specific localisation and interaction dynamics of EVI1 and 
ΔEVI1.
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The EVI1-overexpressing AML cell line SB1690CB was 
maintained as described previously [6]. Further details of 
cell lines in supplementary material. For cell cycle arrest 
in G0/G1 cells were treated with mimosine (200  µM, 
Sigma) for 18 h. For G2/M arrest nocodazole 200 ng/mL 
was used (Sigma) for 24 h. Cells were released from cell 
cycle arrest by washing and continuation of culture in 
fresh media. De novo protein synthesis was blocked with 
10 µg/mL cycloheximide alone, or in combination with the 
proteasome inhibitor MG-132 (5 µg/mL).
Flow cytometry
For cell cycle analysis SB1690CB cell were pelleted 
after individual treatments and time points at 400 × g for 
5 min, then washed twice with cold 1X PBS before to be 
resuspended in 200 µL of cold 1X PBS. Cells were fixed 
by drop-wise adding 800 µL of ice-cold 100% ethanol, 
followed by vortexing and 1-h incubation on ice. After 
2 washes with FACS Buffer (1XPBS, 0.04%  NaN3, 0.1% 
BSA), cells were resuspended in 0.5 mL of FACS buffer 
supplemented with 100 µg/mL propidium Iodine (PI) and 
100 µg/mL of RNase and incubated for 30 min at 37 °C in 
the dark. After incubation, cells were analysed in FACS 
Calibur (BD) flow cytometer.
Western blot, immunofluorescence and antibodies
Protein extracts from pelleted cells were resolved by pro-
tein electrophoresis (NuPAGE® Novex® 4–12% Bis-Tris 
Protein Gels, Invitrogen) and analysed by western blotting 
using standard methodologies.
For immunofluorescence SB1690CB cells were spun at 
200 rpm for 2 min (Cytospin 2, Shandon) onto POLYSINE 
slides (VWR International) and fixed with methanol-free 
4% formaldehyde (Thermo Scientific) for 10 min. Cells 
were washed in PBS and blocked with 5% goat normal 
serum (Cell Signaling Technology) and 0.3% Triton-X100 
(Sigma) containing PBS. Primary antibodies (details listed 
in Supplementary Material) were used with secondary anti-
bodies following standard procedures in a 0.1% BSA (Cell 
Signaling Technology) and 0.3% Triton-X100 containing 
PBS. Single confocal plane and sequential channel acquisi-
tions were performed in a Fluoview1000 confocal system 
(Olympus), using a 60X UPLSAPO oil immersion lens. 
To determine levels of co-localisation of EVI1 and CtBP1, 
Pearson product-moment correlation coefficient (Pearson’s 
coefficient was used to measure the linear signal correlation 
(dependence) between the EVI1 and CtBP1 IF signals. Per-
son’s coefficient ranged from 1 (total positive correlation) to 
− 1 (total negative correlation). 200 + circular (r = 1.5 mm) 
Regions of interest (ROI) were analysed per condition with 
the co-localisation plug-in of the ImageJ software. To dis-
card signal saturated ROIs, the images were analysed using 
HiLo (High-Low) intensity Look Up Table (LUT). Pearson 
coefficients were plotted either in a dispersion graph (cell 
distribution in a single experiment) or as average from at 
least three biological replicates. One-way Analysis Of the 
Variance (ANOVA) with the Tukey post-test statistical 
analysis was used to compare the means (GraphPad Prism). 
Alternatively, linear ROIs of 5 mM in length were analysed 
in terms of signal intensity and plotted as signal histograms. 
Automated foci detection and counting was performed by the 
FociPicker3D plugin for ImageJ [7]. Briefly, nuclear ROIs 
were created for Individual cells at independent microscope 
panels and foci were detected and counted under the follow 
criteria: foci > 0.35 µm in diameter and a MinISetting of 0.5 
(Minimum intensity setting). For the antibodies used, please 
refer to the figure legends and Supplementary Table 1.
Biochemical cell fractionation
2.5 × 107 SB1690CB AML cells were pelleted down at 
300 × g for 4 min (4 °C) and washed 2 times in an excess 
of cold 1X PBS. Cell pellets were sequentially extracted 
with 10 volumes of a base buffer (15 mM KCl, 30 mM 
HEPES pH 7.4, 1 mM TCEP, 2 mM  MgCl2, 1 mM EDTA, 
1 mM  Na3VO4, 1 mM PMSF, 1X Protease Inhibitor Cock-
tail (Sigma P8340), 1X Phosphatase Inhibitor Cocktail 2 
Fig. 1  EVI1 degradation during mitosis. a  Schematic illustration 
of the EVI1 and ΔEVI1 isoforms with numbered zinc finger motifs 
(ZnF), CtBP1 binding motifs (red) and presumed regions of inter-
action with HDAC and BRG1  proteins. b  Upper panel: propidium 
iodine (PI) cell cycle FACS profile of SB1690CB AML cells: asyn-
chronous cells (magenta), synchronised in G0/G1 with Mimosine 
treatment for 18  h (turquoise) and then block-released for 7  h (yel-
low); synchronised in G2/M with a nocodazole treatment for 24  h 
(cyan). Lower panel: Western blot analysis of EVI1 isoforms in 
whole cell lysates from cells arrested as in the top panel. GAPDH 
and  H3 were used as loading controls, CYCLIN E2 as cell cycle phase 
marker and Ser10-phospho  H3 as mitotic marker. c Upper panel: PI 
cell cycle FACS profile of SB1690CB AML cells: Asynchronous 
cells (magenta), synchronised in G2/M with a Nocodazole treatment 
for 24 h (cyan) and then block-released for 1 h (brown), 3 h (yellow), 
7  h (turquoise), 10  h (orange) and 14  h (blue). Lower panel: West-
ern blot analysis as in B, with the addition of CYCLIN B1 as cell 
cycle marker control. d  Western blot analysis of EVI1 isoforms in 
SB1690CB AML cells treated with 10 µg/ml cycloheximide (CHX) 
alone or in combination with 5 µM MG-132 for duration as indicated. 
Due to differences in expression levels of EVI1 isoforms, two expo-
sures are shown and used for quantification purposes. CYCLIN B1 
was used as a control and Ponceau S stain shown for protein loading. 
e Quantitation of EVI1 isoforms and CYCLIN B1 protein levels from 
three independent experiments. (Color figure online)
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(Sigma P5726), 1X Phosphatase Inhibitor Cocktail 3 (Sigma 
P0044), supplemented with: (1) 150 µg/mL digitonin (Sigma 
D141) and glycerol (Fisher Scientific, BP-229-1) to extract 
cytosol proteins; (2) 0.5% Tween-20 (Sigma P1379) and 
glycerol (Fisher Scientific, BP-229-1) to extract soluble 
organelles proteins; (3) 140 mM NaCl to extract Nucleo-
sol proteins; 1% n-Dodecyl β-D-maltoside (Sigma D4641) 
and glycerol (Fisher Scientific, BP-229-1) to extract mem-
brane proteins. The remnant pellet was extracted with 10 
volumes of a high salt lysis buffer [420 mM NaCl, 20 mM 
Bicine (Sigma B3876), 2 mM  MgCl2, 1 µM  ZnCl2, 1 µM 
 CaCl2, 0.6% CHAPS (Sigma C9426), 1 mM  Na3VO4, 1 mM 
PMSF, 1X Protease Inhibitor Cocktail (Sigma P8340), 1X 
Phosphatase Inhibitor Cocktail 2 (Sigma P5726), 1X Phos-
phatase Inhibitor Cocktail 3 (Sigma P0044) and 250 U/µL 
Pierce Universal Nuclease (Thermo Scientific 88,700)] to 
extract chromatin associated proteins. The residual pellet 
was extracted with 2× LDS buffer (Invitrogen) to dissolve 
the nucleoskeleton. Protein extracts were resolved by protein 
electrophoresis using the (NuPAGE® system, Invitrogen) 
and analysed by western blotting.
Results
EVI1 is degraded during mitosis
To investigate endogenously expressed EVI1 in AML we 
studied 3q26 rearranged SB1690CB AML cells, which 
express high levels of both EVI1 and ΔEVI1, but no MDS-
EVI1 (Fig. 1a) [6]. Mimosine treatment-associated G1 arrest 
and release resulted in reduction of both EVI1 and ΔEVI1 
levels (Fig. 1b), with EVI1 only starting to recover 7 h after 
release (Fig. 1b). In contrast, a nocodazole-induced G2/M 
arrest resulted in higher EVI1 levels compared with levels at 
G1 arrest (Fig. 1c), which suggests that degradation of over-
expressed EVI1 occurs during or shortly after mitosis (iden-
tical findings with forced EVI1 expression also in another 
cell line model, see Supplementary Fig. S1). To further test 
this hypothesis, we induced a G2/M arrest and monitored 
EVI1 levels over 14 h post release. We observed gradual 
reduction in EVI1 and ΔEVI1 levels during mitotic progres-
sion with similar patterns as CYCLIN B1 (Fig. 1c), which 
is degraded by the anaphase-promoting complex (APC/
Cyclosome) to exit mitosis [8]. To investigate whether EVI1 
degradation is also proteasome dependent, we blocked de 
novo protein synthesis with cycloheximide alone, or in com-
bination with the proteasome inhibitor MG-132 (Fig. 1d). 
Cycloheximide treatment alone resulted in a marked reduc-
tion of EVI1 levels, which was partly reversed by MG-132 
treatment (Fig. 1d), with patterns resembling those of CYC-
LIN B1 (Fig. 1e). Intriguingly, degradation of ΔEVI1 was 
not reversible to the same extent by MG-132, implying addi-
tional and alternative degradation dynamics for ΔEVI1.
CtBP1 dissociates from EVI1 during mitosis
G1 block and long-term release over 26 hrs confirmed oscil-
lation of EVI1 expression during cell cycle progression, 
exhibiting similar patterns to the MLL protein [9], which 
was used as a control (Fig. 2a). Both EVI1 and ΔEVI1 levels 
recovered at the transition between G1 and S (calibrated by 
the cell cycle markers CYCLIN B1, CYCLIN E2 and p-H3 
(Ser10) (Fig. 2b). With respect to EVI1 interacting proteins, 
we observed for CtBP1 similar cell cycle dependent oscilla-
tion patterns, while the EVI1 interacting proteins BRG1 and 
HDAC1 [10, 11] displayed stable expression levels during 
cell cycle progression. Both EVI1 and ΔEVI1 interact with 
CtBP1 (Fig. 2c), and EVI1 co-localises with CtBP1 most 
strongly during telophase (Fig. 2d, e).
Differential subnuclear distribution of EVI1 
and CtBP1 during interphase
We noticed different patterns of the nuclear signal distribu-
tion of EVI1 and CtBP1 in interphase: The EVI1-signal in 
interphase has a speckled signal distribution (Fig. 3a) in the 
nuclei with distinctly separable foci formations (visualised 
in Fig. 3b, c), whereas the CtBP1-signal was more diffuse 
(Fig. 3a, b, c). Foci counts (Fig. 3d) per region of inter-
est (ROI) were significantly higher for EVI1 foci than for 
CtBP1 (Fig. 3e). To further determine exact protein localisa-
tion within the nucleus, which might underly these findings, 
on cellular fractionation we found abundant CtBP1 in the 
nucleoplasmic fraction (Fig. 3f) (Supplementary Fig. S2). 
However, EVI1, ΔEVI1, and only a fraction of CtBP1 and 
the EVI1-interacting proteins BRG1 and HDAC1 co-elute 
in the nuclear chromatin fraction (Fig. 3f, Supplementary 
Fig. S2). Importantly, a fraction of EVI1, but not ΔEVI1, 
is residing in the nucleoskeleton, evidenced by the presence 
of the nuclear envelop marker LAMIN A/C in that fraction 
(Fig. 3f, g), with similar staining patterns also during mito-
sis as the nucleoskeleton associated protein NuMA1 during 
interphase (Supplementary Fig. S3) [12].
Discusion
High EVI1 expression in one of the most aggressive onco-
genic events in leukaemia, and a similar role for aberrantly 
high EVI1 expression is emerging in some solid tumours 
[13, 14]. Understanding the functional interactions and spa-
tiotemporal associations of the different EVI1 isoforms is 
therefore important. We studied endogenously expressed 
EVI1 and ΔEVI1 in a robust AML cell line model with a 
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Fig. 2  CtBP1 dissociates from EVI1 during mitosis. a  SB1690CB 
AML cells were synchronised in G0/G1 with Mimosine treatment 
for 18 h and then released by replacement with fresh medium. Total 
protein extracts were produced at the time points as indicated after 
release from the G0/G1 block and expression levels of EVI and 
CtBP1 assessed by western blot. Levels of EVI1 interacting proteins 
BRG1 and HDAC1 were assessed as controls, Ser10-phospho  H3 as 
a mitotic marker, CYCLIN B1 and CYCLIN E2 as cell cycle phase 
controls.  MML180 was used as a marker which oscillates through the 
cell cycle and GAPDH as a loading control. b Quantitation of EVI1 
isoform levels as in A from 3 independent experiments. c Co-immu-
noprecipitation of endogenously expressed EVI1 isoforms and CtBP1 
from SB1690CB AML cells. d Dual colour EVI1 (green) and CtBP1 
(magenta) immunofluorescence in SB1690CB AML cells. Single 
confocal planes acquired with a Fluoview 1000 system (Olympus). 
Cell cycle stage assessed by chromatin staining (DAPI, blue). Dashed 
lines denote cell boundaries. e Distribution of the Pearson Coefficient 
(P’sC) for the EVI1 and CtBP1 signal co-localization. 100 circular 
region of interests (ROI) were pooled from 5 different stains (3 µm 
in diameter). Statistical analysis: one-way ANOVA and Tukey post-
test (n.s.=non-significant, ** p < 0.01, *** p < 0.001). (Color figure 
online)
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3q26-aberration associated EVI1 overexpression [6]. Recent 
clinical data support the concept that all 3q-re-arranged 
AMLs constitute a uniform entity driven by EVI1 [2]; we 
therefore presume that our observations apply more gen-
erally to all EVI1-overexpressing AMLs. However, further 
confirmation of our findings in other cell lines and clinical 
samples would be important, also including EVI1-overex-
pressing leukaemia without 3q re-arrangements. Building 
on data showing that forced expression of EVI1 in haemat-
opoietic progenitor cells inhibits normal cell cycle progres-
sion [15], here we illustrate the effect of cell cycle progres-
sion on EVI1. We can demonstrate a bimodal oscillation of 
EVI1 protein levels with maximum EVI1 levels at the end 
of S-phase, similar to that described for related transcription 
factors MLL and GATA2 [9, 16], and imply a role of the 
proteasome for EVI1-degradation, which could also provide 
Fig. 3   Subnuclear distribution 
of EVI1 and CtBP1 during 
interphase. a Dual colour EVI1 
(green) and CtBP1 (magenta) 
immunofluorescence in AML 
cells. Single confocal planes 
acquired with a Fluoview 
1000 system (Olympus) and 
presented individually in grey 
scale. Nucleus visualised by 
chromatin staining (DAPI). 
Signal intensity measured over 
5 µm length (yellow lines num-
bered 1 and 2) linear ROIs for 
both, EVI1 and CtBP1 stains. b, 
c Histogram panels illustrating 
nuclear signal intensity distribu-
tion of EVI1 (green) and CtBP1 
(purple). d Western blotting of 
AML cell fractionations and 
e Quantitation of EVI1 isoform 
levels in selected fraction 
(as in D) from 3 independ-
ent experiments. Statistical 
analysis for each isoform was 
performed by one-way ANOVA 
test and Tukey post-test (n.s. 
non-significant, **p < 0.01, 
****p < 0.0001). (Color figure 
online)
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therapeutic options for EVI1-overexpressing leukaemia. Our 
data further implies that the interaction with the co-repressor 
CtBP1, which has been shown to be essential for some EVI1 
functions [5], is likely to be mainly occurring through inter-
phase and is located in the chromatin fraction and, while a 
large proportion of EVI1 is located at the nuclear matrix, 
where we did not see CtBP1. As the repressor protein CtBP1 
is considered as a therapeutic target in various cancer types 
[17] and might have a role specifically for EVI1 overexpress-
ing malignancies, these observations need to be considered 
when targeting CtBP1 interactions therapeutically. Reported 
differences of functional interactions of the EVI1 isoforms 
with respect to transformation and protein association [4, 
17] may be partly explained by their dynamic sub-nuclear 
localisation. Our study reports on the EVI1-CtBP1 interac-
tion, but many more proteins have been described to interact 
with EVI1 [17, 18]. The detailed mechanistic understanding 
and the functional implications of transcription levels and 
protein turnover, which could be mediated by ubiquitina-
tion, sumoylation or other posttranslational modifications, 
and dynamic spatiotemporal interactions of EVI1 will be a 
critical consideration for targeted therapeutic approaches in 
EVI1 overexpressing leukaemia.
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